MedTrace Logo

Immunogenicity of Concomitant Administration of COVID-19 Vaccines With Influenza Vaccines

NCT06091410 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 62

Last updated 2024-03-26

No results posted yet for this study

Summary

The goal is to evaluate the in-depth immunogenicity analysis (including B-cell and T-cell response) of coadministration of a omicron-containing COVID-19 vaccine and influenza vaccine among healthy adults during 2023-24 season.

Conditions

Interventions

BIOLOGICAL

Omicron-containing COVID-19 vaccine

The COVID-19 vaccine approved for use in the 2023-2024 season

BIOLOGICAL

influenza vaccine

inactivated vaccine containing 15μg hemagglutinin antigen/strain in each 0.5-mL dose, containing four influenza vaccine strains from the 2023-2024 northern hemisphere season

Sponsors & Collaborators

  • Korea University Guro Hospital

    collaborator OTHER

  • Catholic Kwandong University

    lead OTHER

Principal Investigators

  • Min Joo Choi · International St. Mary's Hospital

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-09-25
Primary Completion
2025-02-25
Completion
2025-06-25
FDA Drug
Yes

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06091410 on ClinicalTrials.gov